Status:
RECRUITING
A Study of How the Body Absorbs LY3537031
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
21-70 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to find out how much LY3537031 gets into the blood stream and how long it takes the body to get rid of it when it is injected just under the skin in different parts o...
Eligibility Criteria
Inclusion
- Are overtly healthy as determined by medical evaluation including medical history and physical examination.
- Have a body weight of at least 45 kg.
- Have a Body Mass Index (BMI) within the range of 18.5 and 35.0 kg/m², inclusive
- Do not have skin aberrations that would preclude administration of the study drug at the planned injection sites.
Exclusion
- Have significant history or current cardiovascular, respiratory, hepatic, renal, Gastrointestinal (GI), endocrine, hematological, dermatological, or neurological disorders that, in the opinion of the investigator, are capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.
- Have a history of atopy; that is, severe or multiple allergic manifestations, or clinically significant multiple or severe drug allergies, or hyperesthesia, or severe post treatment hypersensitivity reactions, or have known allergies to LY3537031, Glucagon-Like Peptide-1 (GLP-1) analogs, or related compounds.
- Have undergone any form of bariatric surgery.
- Have a diagnosis or history of malignant disease within 5 years before screening, with the following (some exceptions are allowed)
- Have a history of or current acute or chronic pancreatitis, or elevation in serum lipase or amylase or both greater than 1.5× Upper Limit of Normal (ULN).
- Have a history of chronic liver disease, acute or chronic hepatitis, including a history of autoimmune hepatitis, or any evidence for hepatic impairment.
- Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome Type 2.
Key Trial Info
Start Date :
November 3 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT07202871
Start Date
November 3 2025
End Date
September 1 2026
Last Update
November 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lilly Centre for Clinical Pharmacology
Singapore, Singapore, 138623